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Differing regulation and function of ICAM.1 and class H antigens on
renal tubular cells. Intercellular adhesion molecule-i (ICAM-l) and
MHC class II (Ia) antigens are increased on proximal tubular epithelial
cells (TEC) in autoimmune nephritis and transplant rejection. ICAM-l
is a member of the immunoglobulin gene superfamily that increases the
avidity of T cell interactions with antigen-presenting cells bearing La
antigens. Using an existing mAb and cDNA probe for La antigen, and a
newly described mAb (YN 1/1.7.4) and eDNA probe for murine ICAM-
I, we compared mRNA transcript levels, surface expression and
function of these molecules in transformed TEC derived from normal
(C3H/FeJ) and autoimmune (MRL-lpr) mice. No differences were found
on TEC between these strains of mice. Stimulation of TEC with
interferon-gamma (IFN-y) resulted in the expression of Ia antigens, and
a marked increase of ICAM-1 from basal levels. Increases in ICAM-l
levels occurred with concentrations of IFN-y 10 to 100 times lower (0.5
to 1.0 U/mI) than those required for Ia expression, and preceded Ia
antigen expression by more than 48 hours. Anti-ICAM-i mAb lowered
the binding and antigen-presenting ability of TEC to the A2A2 T cell
hybridoma, suggesting a role for ICAM-1 in immune interactions
between TEC and T cells. Dexamethasone treatment of MRL-lpr mice
abrogated the increase of Ia antigens found in the kidneys of nephritic
mice yet did not reduce the expression of ICAM- I in either kidneys or
cultured stimulated TEC. We conclude that elevated LCAM-l expres-
sion on TEC increases the immune accessory cell capability of TEC
bearing La antigens, and is resistant to down-regulation by some
immunosuppressive agents.
Recognition of foreign antigens by helper T cells requires the
presence of major histocompatibility class II (Ia) antigens on
antigen-presenting accessory (APC) cells. The specificity of the
immune response is provided by the interaction of specific T
cell receptors with antigen presented by APC in the context of
Ia molecules. The avidity of this interaction may be increased
by the expression of other cell surface proteins such as inter-
cellular adhesion molecule-i (ICAM-i), a specific ligand of
lymphocyte function-associated antigen-i (LFA-i) [1—4].
ICAM-i is a 90-114 kDa sialoglycoprotein member of the
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immunoglobulin gene superfamily. It is widely represented on
various tissues, including bone-marrow derived cells [51, vas-
cular endothelium [6], fibroblasts, and some epithelial cells [7].
Constitutive expression varies with cells examined, but activa-
tion studies in humans with interleukin-i, interferon-gamma
(IFN-y), and tumor necrosis factor-alpha (TNFa), indicate that
there is considerable ability to induce ICAM- I, even on tissues
normally expressing minimal amounts [8—i 1]. Two distinct
ICAMs have been identified and cloned in human studies [121.
Although there has been speculation that murine analogues
exist, it was only recently that murine ICAM-l was isolated and
cloned [13, 14].
ICAM- 1 is important in both afferent recognition and efferent
cytotoxic immune responses [15—18]. The relationship between
ICAM-1 and Ia antigens in immune responses is synergistic,
and in cases of limiting Ia expression, ICAM-i may be essential
for antigen presentation [i9]. Renal tubular epithelial cells
(TEC) which are induced by IFN-y to express Ia antigens, can
process and present antigen to lak restricted T cell hybridomas
[20]. Inasmuch as ICAM-1 and Ia antigens are co-expressed in
response to IFN-y and are increased on kidney tubules in
autoimmune nephritis and transplant rejection [20—23], we
chose to study whether major differences in regulation and
function existed between these molecules on transformed TEC.
The expression of ICAM-l is more rapid and requires con-
siderably less IFN-y for induction than Ia antigen. Blocking of
T cell binding and antigen presenting ability by TEC with
anti-ICAM-l mAb indicates ICAM-i is important in the inter-
action between I cells and TEC. We have observed in both
cultured TEC and kidneys of MRL-lpr mice treated with
steroids, a greater effect in down-regulating Ia antigens than
ICAM-l. These findings suggest that up-regulation of ICAM-i
on stimulated TEC in response to cytokines is more resistant to
modulation than Ia antigen expression. Increases in ICAM- 1 on
TEC may be an early event in immune renal injury, and may be
difficult to suppress with immunosuppressive agents. Further-
more, increased levels of ICAM- 1 could accelerate renal injury,
particularly in the initial stages of inflammation, when low
levels of cytokines produced by infiltrating cells resulted in the
expression of low levels of Ia antigens on TEC.
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Methods
Mice
Normal female C3H/FeJ (H2k) and autoimmune MRL/MpJ-
lprllpr (MRL-lpr) (H2k) mice were obtained from The Jackson
Laboratory (Bar Harbor, Maine, USA) and maintained in our
animal facility on standard lab chow.
Materials
Tissue culture media and reagents were obtained from Gibco
(Grand Island, New York, USA), and chemicals were obtained
from Sigma Chemical Co. (St. Louis, Missouri, USA). Mono-
clonal antibodies 10-3.6.2, 10-2.16 (antiIAk), MK-D6 (anti-l-
Ad), R4-6A2 (anti-murine IFN-y), and YN1/l .7.4 (anti-murine
ICAM-l) were prepared as described and concentrated to
approximately 0.5 mg/ml [20, 24]. Anti-LFA-la (M17/4.2) su-
pernatant was provided by Dr. T. Springer (Boston, Massachu-
setts, USA). All antibodies were biotinylated using a standard
protocol. Recombinant murine IFN-y and TNF-a were pro-
vided by Genentech (South San Francisco, California, USA),
and cyclosporin A was donated by Sandoz (East Hanover, New
Jersey, USA). Lipopolysaccharide (LPS, S. minnesota) was
from Calbiochem (La Jolla, California, USA). The following
stock solutions were made: hydrocortisone was dissolved in
ethanol at 102 M, calcium ionophore A23 187 in DMSO at 10
M, and cycloheximide in distilled water at 2 mglml.
Dexamethasone treatment of mice
Dexamethasone sodium phosphate (Elkins-Sinn Inc., Cherry
Hill, New Jersey, USA) was added to the drinking water of 10
female MRL-lpr mice starting at age seven weeks, and the
concentration was adjusted to maintain a daily steroid intake of
0.4 mg/kg based on daily water consumption. A control group
received untreated water ad libitum. Animals in both groups
were sacrificed at age 23 weeks, and whole kidney tissue was
prepared for RNA extraction.
Cell cultures and cell lines
The establishment of C3H/FeJ (Cl, Cl.l) and MRL-lpr
(M3. 1) derived clonal cell lines by transformation of proximal
tubular cells with origin-defective SV4O DNA is described in
detail elsewhere [20]. The porcine tubular epithelial cell line
LLC-PK1 was obtained from the American Type Culture Col-
lection [25]. These epithelial cells were grown in modified Kl
medium (50:50 mixture of DMEM and Ham's Fl2 medium,
containing 5% fetal calf serum, FCS) and hormonal additives as
described [20], and passaged by trypsinization. The lak re-
stricted T cell hybridoma A2A2 recognizes hen egg lysozyme
(HEL) [26]. IL-2 dependent HT-2 cells were provided by Dr. K.
Rock (Boston, Massachusetts, USA).
RNA preparation and Northern blot analysis
Total RNA was isolated from homogenized kidney tissue or
confluent monolayers of transformed TEC with a single-step
acid guanidium isothiocyanate-phenol-chloroform extraction
method [27, 28]. Total RNA (25 jxg) was denatured with 1 M
glyoxal and 50% dimethylsulfoxide, electrophoresed through a
1.5% agarose gel, and transferred onto Gene Screen nylon
membranes (New England Nuclear, Boston, Massachusetts,
USA). The RNA was baked onto the membrane at 80°C for four
hours, and blots were prehybridized with l.Sx SSPE, 1% SDS,
0.5% (wt/vol) non-fat skim milk and 0.5 mg/mI salmon sperm
DNA for three hours at 60°C. The cDNA insert of K4- 1.1 clone
encoding the murine ICAM-l [13] was isolated by EcoRI
digestion of the plasmid. The source and nature of the genomic
probe for A has been described [29]. Probes were radiola-
beled by primer extension using random hexanucleotides [30].
Blots were hybridized for 16 to 24 hours at 42°C and were
washed at room temperature with 2x SSC, 0.1% SDS; 0.5x
SSC, 0.1% SDS; and 0.1 x SSC, 0.1% SDS for 15 minutes each,
and subsequently with 0.1 x SSC, 0.1% SDS at 65°C for one
hour. After hybridization the blots were exposed to Kodak
X-AR film. All blots were also rehybridized with /3-actin to
ensure that approximately equal amounts of RNA were loaded
for electrophoresis. In whole kidney preparations, steady-state
mRNA transcript levels were quantified using scanning densi-
tometry (Biosoft, Milltown, New Jersey, USA). The ratio of
ICAM-l/f3-actin and IaJ/3-actin was then calculated for each
sample within a treatment group (N 9) to standardize RNA
levels and allow quantitative comparison of mean values be-
tween groups.
Limulus endotoxin assay
Samples of medium, including all additives were assayed for
LPS contamination by the Limulus amoebocyte assay (Associ-
ates of Cape Cod, Wood's Hole, Massachusetts, USA) accord-
ing to the protocol provided. The lower limit of detection for
this assay was 0.125 EU/mI and the lowest concentration of
LPS standard used that provided a positive result contained 25
pg of LPS (E. coli 0113).
Flow cytometry
Primary cultures of cortical TEC, and SV4O transformed
TEC were gently trypsinized to remove them from the plates.
ICAM-l expression was measured with biotinylated mAb YN1/
1.7.4, and Ia antigen expression with mAb 10-2. 16. Phycoery-
thrin-conjugated streptavidin or fluorescein (FITC)-conjugated
affinity-purified goat anti-mouse IgG (F(ab')2 fragment were
used as secondary step. Cells without primary antibody or with
irrelevant biotinylated isotype matched antibody served as
controls. Cells were analyzed with an Epics flow cytometer.
Cell adherence assays
TECwere grown in collagen-coated 96-well flat bottom plates
for 24 hours prior to the addition of cytokines or fresh medium
as control. In blocking experiments, mAbs were added at 1:50
to 1:70 dilutions (10 to 15 sg/ml), and supernatants at 1:10 to
1:20 final concentration. A2A2 cells were labeled for 1.5 hours
on a rocking platform, with 200 to 300 Ci of Na51CrO4 in 300
d of medium containing 50 p1 FCS, and washed three times
before use. The A2A2 cells were layered on TEC monolayers,
briefly centrifuged (600 rpm x 30 seconds) and incubated for
two to three hours at 37°C. Non-adherent cells were removed
from the wells by gently washing with 100 p1 aliquots of warmed
medium for a total of six to eight washes, holding the plates at
a 45 degree angle. Washes were identical for all wells within
each experiment. To obtain total cpm, the cells were lysed with
the addition of 0.1 N NaOH. One hundred microliters of
supernatant was added to 3 ml Liquiscint (National Diagnos-
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tics, Somerville, New Jersey, USA), and read on a LS18O1 Beta
counter (Beckman Instruments, Irvine, California, USA).
Antigen presentation
Transformed TEC and freshly isolated C3H/FeJ TEC were
cultured for three days in the presence or absence of IFN-y (500
U/ml and 100 U/mI, respectively). Antigen presentation was
then determined by incubating TEC with the Iakrestricted T
cell hybrid A2A2 specific for HEL. Such hybrids secrete IL-2
when co-cultured with Ia-matched antigen presenting cells in
the presence of the appropriate foreign antigen. Serial dilutions
of TEC (1 x io, 3 x 1O, 1 x io and 3 x l0) were co-cultured
with io T hybrid cells in 96 well plates with 50 pg/well of HEL.
In blocking experiments mAb were used at 1:50 to 1:70(10 to 15
gIml), and supernatants at 1:10 to 1:20 final concentration.
After 24 hours, 100 pi of supernatant per well was collected and
assayed for IL-2 in a secondary culture using HT-2 cells, an
IL-2 dependent T cell line. HT-2 cells (5 X l0) were cultured
for 24 hours in the presence of serial dilutions of the primary
culture supernatant. The degree of stimulation was determined
by HT-2 cell proliferation (in arbitrary U/rnl of IL-2) according
to Kappler et a! [31]. Results were confirmed by a colorimetric
assay using 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazoli-
urn bromide (MTT) and optical density at 570 nm, as previously
described [32]. The assays were highly correlated and provided
similar results.
Statistics
Statistical analysis, where applicable, was performed using
Statview SE+ (Abacus Concepts, Berkley, California, USA).
Differences between groups were compared by one way anal-
ysis of variance and unpaired t-tests. All results are expressed
as mean SEM.
Results
ICAM-1 is induced more rapidly than ía antigens on cultured
TEC
Cl cells were grown in modified K1 medium and 250 U/mi of
IFN-y was added at various time points up to 72 hours. Surface
expression of ICAM- 1 was rapid and reached nearly 90% of
maximum within six hours (Fig. 1A). Thus the percentage of
positive cells did not increase markedly after 24 hours. By 72
hours, mean fluorescence intensity increased, indicating in-
creased surface density per cell with time. Concurrent labeling
with 10-2.16 mAb, demonstrated no basal expression of IAk
antigen. Elevated levels of I-A' did not appear until 48 hours
(13.8% positive cells), with a maximum reached at 72 hours
(46.5%). The kinetics of ICAM-l mRNA induction was similar
to surface expression with increased mRNA noted by six hours
and maximal induction by 24 hours (Fig. 1B).
ICAM-1 is induced more readily than ía antigens in response
to IFN-y
The induction of ICAM-1 on Cl and M3.1 cells by varying
doses of IFN-y (0.5 U/mi to 100 U/mi) was studied (Fig. 2).
Results are representative of three experiments. Cl cells had a
higher basal expression of ICAM-1 than M3.1 cells (38 to 58%
vs. 16 to 26%) in separate experiments. Cells were grown to the
same degree of confluence to eliminate any effect of cell density
on ICAM-l levels. To determine if LPS contamination of the
medium was responsible for the variable basal expression of
ICAM-l in our cells lines, medium was screened for endotoxin
and found to have less than 0.125 EU/mI or 25 pg/mI of
standard, as determined by the Limulus amoebocyte assay.
ICAM-i expression with LPS requires considerably higher
concentrations (>1 ng/ml) in our cell lines (unpublished obser-
vation). ICAM-l expression in both cell lines was increased
with very low levels of IFN-y (0.5 to 1 U/mi) and was dose
dependent at the lower concentrations. In Cl cells, maximal
expression occurred with 100 U/mI of IFN-y, with greater than
80% becoming positive. There was no further augmentation at
concentrations up to 500 U/mI (not shown). ICAM-1 on M3.l
cells displayed a similar sensitivity to IFN-y, but showed little
increase with IFN-y concentrations >10 U/mI. Expression of
surface Ia antigen was considerably less responsive to IFN-y.
Ia was not detectable with less than 100 U/mI of IFN-y (23% vs.
6% with 50 U/mi) at 72 hours. In Ci cells, concentrations of
IFN-y >100 U/mI did not markedly increase the expression of
Ia antigen.
ICAM-1 gene regulation in TEC differs from ía antigens
Cl cells were treated with cycloheximide (5.0 jig/mI) with or
without IFN-y (Fig. 3). RNA was extracted after 24 hours and
analyzed by RNA blot analysis. Control cells showed basal
expression of ICAM-l mRNA, which was up-regulated by
IFN-y within 24 hours, as was Ia mRNA. Interestingly, cyclo-
heximide alone caused induction of ICAM- 1 mRNA but not Ia
mRNA. Cycloheximide when given for 12 hours followed by
IFN-y, increased ICAM-l mRNA, but had no greater effect
than with IFN-y, or cycloheximide given alone for 24 hours.
Cycioheximide given concurrently with IFN-y for 24 hours
caused a superinduction of ICAM- I mRNA, and prevented any
increase in mRNA for Ia. In separate experiments, neither
cyclosporin A nor calcium ionophore A23l87 (10—v M) alone
induced ICAM-l (Fig. 4). Cyclosporin A (5 jig/mI) was unable
to block ICAM-l gene induction once TEC were exposed to
IFN-y. ICAM-1 mRNA was increased by TNFa and IFN-y,
and a synergistic response which we have previously observed
with surface expression [32], was achieved using both cytokines
(Fig. 4). The surface level of ICAM-1 on M3.1 cells was
increased with TNFa alone. By flow cytometry, a basal surface
level of 17% positive cells increased to 38% with 12 hours of
TNFa (50 ng/ml) stimulation. The magnitude of response using
TNFa was less than IFN-y alone, and relatively high concen-
trations of TNFa were required for effect (>10 ng/ml).
JCAM-1 expression is resistant to down-regulation by steroids
Since we have previously shown that steroids can down-
regulate steady state mRNA levels for Ia antigens in stimulated
TEC, we wished to determine if they could also alter ICAM-1
levels [20]. Concentrations of hydrocortisone known to reduce
Ia antigen expression (10—i M) were unable to reduce either
surface expression (Table 1) or mRNA induction of ICAM-l in
TEC stimulated with IFN-y. Comparison of ICAM-l//3-actin
mRNA ratios showed that the increase in cells treated for 24
hours with 100 U/mI of IFN-y (0.133 vs. 0.128 in unstimulated
controls) was not decreased in cells treated concurrently with
IFN-y and 5 x l0 M hydrocortisone (ratio = 0.147). The
results with dexamethasone treated MRL-lpr mice were similar.
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Nine animals were examined from each group. Steady-state
mRNA transcript levels for ICAM-1 and Ia antigens were
compared between treatment group kidneys, and a clear differ-
ence was found in the mean Ia/f3-actin mRNA ratios between
the untreated and treated animals (2.32 0.48 vs. 0.64 0.05,
P <0.01). There was a modest reduction of ICAM-l expression
in the treated group which did not achieve statistical signifi-
cance (0.28 0.03 vs. 0.19 0.03, P = 0.07).
Anti-IFN-y mAb blocks expression of Ia but not ICAM-1
Anti-IFN-ymAb was used to block IFN-y stimulation ofCl.1
cells (Fig. 5). The results shown are representative of two
experiments performed. Culture medium containing IFN-y (100
U/mI) and mAb was incubated for 20 minutes before their
addition to the cells. At 24 hours, no steady state mRNA levels
for Ia were evident at all dilutions of mAb. However, ICAM-l
expression was unaffected and remained elevated at all dilu-
tions of mAb. To confirm that this effect was due to the extreme
sensitivity of ICAM-1 to IFN-y, Cl. I cells were incubated with
Fig. 1A. Time course of IFN-y stimulated
ICAM-1 surface expression in Cl cells. Cl
cells were pulsed with 250 U/mi IFN-y at
various time points from 3 to 72 hours,
trypsinized, labeled with YN1/1,7.4, and
assessed for ICAM-1 expression by flow
cytometry. Basal level of positive cells was
58% (unstimulated), and with stimulation, a
maximum by 24 hours of 88.5% positive cells.
Controls shown are cells with phycoerythrin
(PE)-conjugated streptavidin and no primary
antibody. B. RNA blot analysis of ICAM-l
gene expression over 48 hours after
stimulation of Cl cells with IFN-y (100 U/mI).
Lanes I to 6 represent RNA obtained after 0,
3, 6, 12, 24, and 48 hours of stimulation,
respectively. The blot was rehybridized with
/3-actin to ensure equal loading of RNA in all
lanes (lower bands).
culture media containing only 2.5 U/mi of IFN-y which was
pre-incubated with anti-IFN-y mAb. ICAM-l levels were as-
sessed by FACS. ICAM-1 levels increased with IFN-y at 12
hours as compared to unstimulated controls (68% vs. 54%
positive cells), and this effect was indeed blocked by pre-
incubation with 5 g/ml of anti-IFN-y mAb (52%).
ICAM-l is required for T cell adherence to renal TEC
To study the role of ICAM- 1 in the adherence of cells to TEC,
M3.1 and Cl cell monolayers were stimulated with IFN-y (250
U/mi) and TNFa (100 ng/ml) for 24 hours. Unstimulated TEC
were used as control. A2A2 cells labelled with 51Cr were added
to the monolayers, and total cpm were obtained from the
adherent cells remaining after washing. A2A2 T cell hybrids
were used for adherence, as they represented a uniform popu-
lation of cells, and flow cytometric analysis demonstrated a high
surface expression of LFA-1 (not shown). The results shown
are representative of two experiments performed. There was a
four- to fivefold increase (P < 0.01) in A2A2 adherence with
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Fig. 2. Effect of JFN-y concentration on ICAM-I surface expression with CI and M3.I cells. In separate experiments, cells were treated with
various doses of IFN-yfor either 24 (M3.l cells) or 72 hours (Cl cells), trypsinized, labeled with YNIII.7.4, and assessed for ICAM-l expression
by flow cytometry. Basal positive levels were 38% for Cl cells and 26% for M3. I cells. Maximum levels were 81% for Cl cells with 100 U/mI IFN-y
and 84% for M3.1 cells with 50 U/mI IFN-y. Controls shown are cells with phycoerythrin (PE)-conjugated streptavidin and no primary antibody
(Cl), or with biotinylated irrelevant antibody (M3. 1 cells).
3 5
Fig. 3. RNA blot analysis of the effect of cycloheximide on ICAM-I
and/a gene expression in CI cells. Lane I, unstimulated cells; lane 2,
IFN-y 500 U/mI, for 24 hours; lane 3, cycloheximide 5 g/ml, for 12
hours followed by IFN-y 500 U/mi, for 12 hours; lane 4, IFN-y plus
cycloheximide 5 sg/ml, for 24 hours; lane 5, cycloheximide 5 sg/ml, for
24 hours. Blots were reprobed separately for /3-actin.
stimulated Cl and M3.l monolayers as compared to control.
This increase was significantly (P < 0.01) but incompletely
blocked (40 to 60%) by both anti-ICAM and anti-LFA- 1 mAb
Fig. 4. Synergistic effect of IFN-y and TNFcr on ICAM-1 gene expres-
sion. Cl cells were stimulated with cytokine for 24 hours and total RNA
was analyzed by RNA blot. Lane 1, control unstimulated cells; lane 2,
IFN-y, 100 U/mi; lane 3, TNFa, 100 ng/ml; lane 4, IFN-y and TNFa;
Lane 5, cyclosporine, 5 gg/ml; Lane 6, cyclosporine and IFN-y; Lane
7, calcium ionophore A23l87 (l0- M).
(Fig. 6). Antibody against Ia antigens did not reduce adherence
(not shown). As an additional control, adherence of A2A2 cells
to porcine epithelial LLC-PK, monolayers was found to be
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Table 1. ICAM-! expression on stimulated M3. I cells is resistant to
hydrocortisone
% Positive Mean log
Treatment cells fluorescence
IFN-y Unstimulated 19
IFN-y50 U/mI 72
IFN-y + hydrocortisone 695 x 1O M
IFN-y + hydrocortisone 81
5 x i0 M
80
124
122
122
Cells were grown in media, media with IFN-y (50 U/mI) or media with
both IFN-y and HC for 12 hours. Cells were labelled with YN1/l.7.4
and assessed for ICAM-1 expression by flow cytometry. Data is
presented as % positive cells and mean log fluorescence.
Fig. 5. RNA blot analysis of JCAM-1 and Ia gene expression in Cl.!
cell lines using anti-murine IFN-y mAb (R4-6A2). All stimulated cells
received IFN-y, 100 U/mI for 24 hours. Lane 1, Cl. 1 unstimulated
control; lane 2, C1.l + IFN-y; lane 3, Cl.1 + IFN-7 + R4-6A2 (0.5
g/ml); lane 4, Cl.i + IFN-y + R4-6A2 (5.0 ig/ml); lane 5, Cl.l +
IFN-y + R4-6A2 (50.0 j.g/ml).
minimal and was not influenced by cytokine or antibody treat-
ment. LLC-PK1 do not express ICAM-l defined by YNI/1.7.4.
ICAM-1 alters the antigen presenting ability of TEC
Since IFN-y stimulated TEC can process and present antigen
to lak restricted T cell hydridornas [201, we studied whether
ICAM-l played a role in antigen-presenting ability by kidney
cells. TEC were stimulated with IFN-y (500 U/mI) for 72 hours
to allow expression of both ICAM-l and Ia antigens; unstimu-
lated cells were used as the control. Stimulated TEC were
pre-incubated with anti-ICAM-l mAb, anti IAk mAb or fresh
medium alone before the addition of A2A2 cells and HEL
antigen. Table 2 shows that unstimulated TEC and TEC treated
with anti.IAk mAb were unable to present antigen. In a
separate experiment, the results with freshly isolated cortical
TEC from C3H/FeJ mice were similar, thereby eliminating the
possibility that SV4O transformation of the cells altered their
antigen-presenting ability (Table 3). Stimulated TEC treated
with anti-ICAM-l mAb, showed up to a threefold reduction in
Fig. 6. Adherence of51Cr labeled A2A2 T cell hybridoma cells to renal
tubular cell monolayers stimulated with IFN--y (250 U/mi) and TNFa
(100 ng/ml) for 24 hours. Stimulated monolayers were also treated with
anti-ICAM mAb or anti-LFA-la supernatant and were compared with
stimulated and unstimulated controls. Total cpm of the adherent cells
were determined by the addition of 100 d of 0.1 M NaOH as described
in Methods. Treatment groups were as follows: unstimulated control
monolayers (open bars), stimulated cells without antibody (black bars),
anti-ICAM-l mAb (stippled bars), and anti-LFA-la (striped bars). The
effect of anti LFA- I a on adherence to LLC-PK1 monolayers was not
determined.
Table 2. Anti-ICAM-i and anti-la mAb treatment of transformed
TEC inhibits antigen presentation
mAb treatment Number of antigen
of TEC presenting cells
Cell
type IFN-y
anti- anti-
Ia ICAM-l I-A" 3 x l0 1 X iO
Cl —
+
+
÷
— — — <20 <20
+ — — >160 >160
+ + — 80—160 20
+ — + <20 <20
M3.l —
+
+
÷
— — — <20 <20
+ — — >160 >160
+ + — >160 40
+ — + <20 <20
Various numbers of IFN-y stimulated TEC (3 X l0 and 10) were
pre-treated with anti-LCAM-l mAb (YN 1/1.7.4), anti-I-A" (10-2.16)
mAb or medium for 2.5 hours before being co-cultured with IO
HEL-specific lakrestricted A2A2 cells for 24 hours. HEL (50 .tg/we1l)
was added to all wells. Supernatants were assayed for IL-2 content in
the HT-2 assay. Results are expressed in arbitrary U/mi of IL-2. Results
are shown for l0 and 3 x io antigen presenting cells. La expression
was determined by flow cytometry.
antigen-presenting ability, which was more marked when fewer
stimulated Ia bearing TEC were used in the initial incubation
(Table 2). In similar experiments, treatment of TEC with
anti-LFA- 1 mAb reduced antigen-presenting ability to the same
extent as anti-ICAM- 1 mAb (not shown). A mAb recognizing
IAd (MK-D6) had no effect on antigen presentation (Table 3).
Discussion
Increased expression of both ICAM- 1 and Ia antigens on
proximal tubular cells occurs in the kidneys of autoimmune
MRL-lpr mice prior to overt renal disease [21, 28] and in human
kidneys during allograft rejection [22, 23]. We have speculated
that the increased expression of these molecules allows proxi-
mal tubular cells to stimulate T cells and accelerate, if not
initiate, renal disease in autoimmune mice. These molecules
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Table 3. Anti-ICAM-1 and anti-Ia mAb treatment inhibit antigen
presentation of freshly isolated C3H/FeJ kidney TEC
Number of antigen
mAb Treatment of TEC presenting cells
anti- anti- anti
Cell type IFN-y ICAM-l I-At' I.Ad 3 x l0 I x l0
C3H/FeJ — — — — <20 <20
+ — — — >160 80-160
+ + — — 40 20
+ — + — 20 <20
+ — — ÷ >160 >160
IFN-y stimulated TEC (3 x iO and l0) were pre-treated with
anti-ICAM-l (YNl/l.7.4)oranti-I-A'(l0-2. 16) mAb, anti I-M(MK-D6)
supernatant, or media for 2.5 hours prior to being co-cultured with iO
HEL-specific Ia'-restricted A2A2 cells for 24 hours. HEL (50 pg/well)
was added to all wells. Supernatants were assayed for LL-2 content in
the HT-2 assay. Results are expressed in arbitrary U/mI of IL-2.
may also act to promote allograft rejection in renal transplan-
tation. TEC stimulated with IFN-y to express Ia antigens act as
immune accessory cells, a finding shared with many cell types
[20, 33—37]. However, the avidity of interactions between cells,
and the efficiency of antigen presentation may be influenced by
adhesion molecules such as ICAM-l [19].
ICAM-l, like Ia antigens, is a member of the immunoglobulin
gene superfamily, and increased levels can be detected on
various cells including proximal tubules, in autoimmune dis-
eases and allograft rejection [7, 20—23, 28, 38]. Previous studies
of ICAM-l have not examined the relationship of ICAM-l and
Ia antigens in cultured renal tubular cells. A newly described
mAb (YN1/l.7.4) and cDNA probe for murine ICAM-l enabled
us to identify differences in regulation and function between
these surface immune molecules [13, 24]. TEC from normal
C3H/FeJ and autoimmune MRL-Ipr mice were transformed and
cloned to allow extensive studies of tubular cells in culture
These cells have been previously characterized and shown to
retain highly differentiated characteristics of proximal tubular
cells [20].
The elevation of ICAM- I and Ia antigens on TEC in models
of immune renal injury may be related to the release of
cytokines by infiltrating cells within the kidney. The magnitude
of cell surface expression depends not only on the amount and
type of cytokines in the microenvironment, but also on the
sensitivity of cells to those cytokines. Since the increased
expression of ICAM- 1 and Ia antigens is related to immune
renal injury, we were interested in the response of TEC to
various cytokines, particularly IFN-y. We found that the
amount of IFN-y required to induce ICAM-1 expression was
several orders of magnitude less than the amount required for La
antigen expression. This sensitivity was emphasized by the
ability of anti-IFN-y mAb to block La but not ICAM-l expres-
sion by TEC, unless a very low level of IFN-y was used for
stimulation. Despite the prominent increased expression of
both antigens on proximal tubular cells in mice with lupus
nephritis, we did not detect differences in the expression of
these antigens in TEC derived from normal mice and those with
lupus nephntis. This suggests that in the MRL-lpr model of
autoimmune nephritis, up-regulation of these molecules is re-
lated to the amount or type of cytokine present within the
kidney, rather than an intrinsic altered sensitivity of TEC to
cytokine stimulation. Our data also suggests that in cases of low
levels of cytokines, up-regulation of ICAM-l could occur on
TEC without a corresponding increase in Ia antigen expression.
This would be particularly evident in the early stages of
inflammation, since unlike Ia antigens which require several
days for expression, ICAM-l is increased on TEC to nearly
maximal levels within hours of cytokine stimulation. Rapid
expression of ICAM- 1 appears to be a general property of this
molecule and has been described in several cell types, including
fibroblasts and keratinocytes [39].
ICAM- 1 levels on TEC are influenced by cytokines other
than IFN-y, including IL-i a and TNFa, and we have noted that
a synergistic response occurs in TEC with the combination of
TNFa and IFN-y [8, 9, 28, 39]. The pattern of ICAM- 1 response
by TEC to cytokines differs from other cells, such as endothe-
hal cells, which have a predominant response to TNFa and
IL-I a and are affected by IFN-y [39]. Ia antigens on TEC are
increased exclusively with IFN-y, indicating that a marked
difference exists in the regulation of these molecules [20]. Our
results with cycloheximide emphasize this difference. Superin-
duction of ICAM-l mRNA in cells treated with cycloheximide
may be due to the loss of a labile repressor, while the inability
to induce Ia antigen mRNA in the presence of cycloheximide
confirms the observation that a protein intermediate is required
[20]. The modulation of ICAM-1 levels by multiple cytokines
may promote lupus nephritis, as IL-i, TNFa and IFN-y are all
increased in kidneys of nephritic MRL-lpr mice [40—42]. Fur-
thermore, in inflammatory renal disease, the expression of
ICAM-l on TEC would not be dependent on LFN-y producing
T cells, but could also be induced with cytokines generated by
either infiltrating macrophages and monocytes, or intrinsic
renal mesangial and endothelial cells.
The specificity and strength of interactions between helper T
cells and antigen presenting cells requires Ia antigens and
ICAM-l [43]. Using an in vitro assay, we demonstrated that
both ICAM- I and LFA- I were equally important for T cell
binding to TEC. Complete blocking of antigen presentation by
TEC with anti-Ia mAb confirmed the essential nature of these
molecules in activating T cells [201. Blocking of antigen presen-
tation with anti-ICAM-1 mAb was most efficient in cultures
with few La bearing TEC. This finding is consistent with the
concept that the ICAM-l/LFA-l ligand is more important in low
avidity T cell/APC interactions, as might be the case with
sub-optimal levels of Ia antigens or sub-optimal APC. In recent
studies, transfection of human ICAM-1 genes into L-cells
constitutively bearing few Ia molecules, confers antigen-pre-
senting ability to those cells [19]. Incomplete blocking of T cell
activation by anti-ICAM-l mAb may have been due to a
number of reasons. Anti-ICAM-i mAb may not be an efficient
blocker, or other higands such as ICAM-2 and LFA-3 which are
likely expressed on TEC, may have bound to the appropriate T
cell higands (LFA- 1 and CD2, respectively), and influenced our
results [38, 441. The A2A2 T cell hybrid has been noted to be a
"high affinity" cell, and greater blocking might have been
observed using a cell with a lower avidity for antigen [45].
The importance of adhesion molecules is becoming increas-
ingly recognized in transplantation and autoimmunity. Target-
ing of these molecules with either specific mAbs or down-
regulation with broadly immunosuppressive agents may
become important therapeutic modalities [22]. Steroids may act
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directly on cells or may alter complex cellular interactions
[46—48]. The down-regulation of Ia antigens but not ICAM-l
expression in cultured TEC appears to be due to a direct
response of TEC to steroids. Similarly, dexamethasone given to
MRL-lpr mice was unable to reduce ICAM-l mRNA expression
in the kidney, yet caused a marked down-regulation of Ia
antigen mRNA expression. Broadly acting immunosuppressive
agents may not modulate ICAM-l levels on non-lymphoid
tissue. The question remains, however, whether specific mAb
therapy can modulate ICAM-l levels, and thus whether anti-
ICAM-l mAb will be beneficial in autoimmüne lupus nephritis
and renal allograft rejection.
In summary, we have examined both ICAM-l and Ia antigens
on kidney tubular cells in the mouse. Several features of
ICAM-l expression on TEC are similar to Ia antigens, namely,
an increase in expression in response to IFN-y and a role in
antigen presentation. However, this study emphasizes several
important differences between these molecules in TEC. ICAM-
1 is induced by several cytokines including IFN-y and TNFa, in
contrast to Ia antigens which are induced exclusively by IFN-y.
ICAM-l is more readily and rapidly expressed on TEC in
response to IFN-y, and thus expression is not coordinate with
La antigens. Following induction, ICAM-l is refractory to a
pharmacologic agent known to reduce Ia. The reduction in the
antigen-presenting ability of TEC by anti-ICAM- 1 mAb sug-
gests a role for ICAM-l in immune interactions between TEC
and T cells. We speculate that the expression of ICAM-1 in
response to low levels of cytokines facilitates TEC bearing Ia
antigens to participate in immune interactions and thus is
important in the early inciting events leading to autoimmune
lupus nephritis and transplant rejection.
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